Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899580 | 1.00 | CYP2C19 (0.47) | CYP2C19HIF1ACYP1A2LMNAHTT | |
| SCHEMBL5570579 | 1.00 | CYP2C19 (0.47) | CYP2C19HIF1ACYP1A2LMNAHTT | |
| Ammonia Solution, Strong SCHEMBL3396016 | 0.98 | CYP2C19 (0.45) | CYP2C19HIF1ACYP1A2LMNAHTT | |
| SCHEMBL22722995 | 0.90 | CYP2C9 (0.58) | LMNAHTTL3MBTL1MAPTKMT2A | |
| SCHEMBL22722994 | 0.90 | CYP2C9 (0.58) | LMNAHTTL3MBTL1MAPTKMT2A | |
| SCHEMBL14723764 | 0.84 | CYP2C19 (0.45) | CYP2C19HIF1ACYP1A2LMNAHTT | |
| SCHEMBL28759248 | 0.84 | CYP1A2 (0.43) | CYP2C19HIF1ACYP1A2LMNACYP2D6 | |
| SCHEMBL10539630 | 0.84 | MIF (0.48) | CYP2C19HIF1ACYP1A2HTTL3MBTL1 | |
| SCHEMBL28133333 | 0.83 | ACHE (0.46) | CYP2C19HIF1ACYP1A2CYP2C9HDAC3 | |
| SCHEMBL8015531 | 0.83 | CYP2C19 (0.46) | CYP2C19HIF1ACYP1A2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| CN-101380317-B | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD | 2010-12-08 | — | — | CN | claimed |
| EP-1685248-B1 | OXIDOREDUCTASE FROM METSCHNIKOWIA ZOBELLII | IEP GMBH (DE) | 2010-06-09 | — | — | EP | claimed |
| EP-2033635-A1 | Short-chain fatty acid derivatives for treating pruritus | Asan Laboratories Company (Cayman) Limited (CN) | 2009-03-11 | — | — | EP | claimed |
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| US-20080107646-A1 | Administering phenylbutyric acid derivative and pharmaceutically acceptable carrier | Sunny Pharmtech Inc. (TW) | 2008-05-08 | — | — | US | claimed |
| CN-101087768-A | Thrombopoietin activity modulating compounds and methods | LIGAND PHARM INC (US) | 2007-12-12 | — | — | CN | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-6403646-B1 | ADMINISTERING PHENYLBUTYRIC ACID OR DERIVATIVES TO TREAT LIVER DISEASE AND EMPHYSEMA CAUSED BY PROTEASE INHIBITOR TYPE Z MUTATION; STIMULATES SECRETION WITHOUT INCREASING SYNTHESIS OF PROTEIN | PERLMUTTER DAVID H (US) | 2002-06-11 | — | — | US | claimed |
| JP-2119785-A | — | — | None | — | — | JP | disclosed |
| US-12295394-B2 | Water-soluble additive composition | SUMITOMO BAKELITE CO., LTD. (JP) | 2025-05-13 | — | — | US | disclosed |
| WO-2025025245-A1 | LIGHT-EMITTING DEVICE, PREPARATION METHOD, AND ELECTRONIC APPARATUS | 纳晶科技股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025025244-A1 | LIGHT-EMITTING APPARATUS, PREPARATION METHOD AND ELECTRONIC DEVICE | 纳晶科技股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| JP-H02119785-A | PRODUCTION OF 2-OXO-4-PHENYLBUTYRIC ACID | TORAY IND INC | 1990-05-07 | — | — | JP | disclosed |
| EP-0037697-B1 | DIOXOLANE DERIVATIVES FOR USE AS CHEMICAL INTERMEDIATES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-01 | — | — | EP | disclosed |
| US-4348322-A | Dioxolane derivatives | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-09-07 | — | — | US | disclosed |
| EP-0037697-A1 | Dioxolane derivatives for use as chemical intermediates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | disclosed |
| EP-0037698-A1 | Benzaldehyde derivatives for use as a chemical intermediate | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | CYP2C19 1347/4885HIF1A 4197/4885CYP1A2 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.